Is cancer prevention ever going to be profitable?
Undoubtedly, the war on cancer is an expensive endeavour. It is estimated that, where data are available in Europe (e.g. Germany and France), cancer care accounts for a similar proportion of overall health-care expenditure to that in the USA, i.e. approximately 5%. Currently, no society can afford all of the potential cancer treatments for all the patients that could benefit from them. How the required resources should be provided is one of the great on-going debates, and different countries approach this problem in different ways. Additionally, the more we understand about the pathology, pathogenesis, diagnosis and treatment of cancer, the more options are created. Many of these options are new diagnostic tools and more effective treatments. Obviously these innovations, paired with an increasing patient pool, are leading to tremendous health-care expenditures, well surpassing current budgets. Hence, the question arises of how many resources should be devoted to the management of cancers, given that resources are scarce and many other fields and specialities are competing for these resources. This paper addresses the question of whether preventive measures in oncology eventually pay off.
Szucs
Thomas D
TD
Institute of Social and Preventive Medicine, University of Zurich, Switzerland. Thomas.szucs@ifspm.uzh.ch
Dedes
Konstantin J
KJ
D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics*; D006801:Humans; D009369:Neoplasms / Q000191:economics*